Skip to content

ENDOBARIHEART STUDY

CARDIOVASCULAR RISK PROFILE IN HIGH CARDIOVASCULAR RISK OBESE PATIENTS BEFORE AND AFTER ANDOSCOPIC SLEEVE GASTROPLASTY: A PILOT STUDY

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07847307
Enrollment
50
Registered
2026-09-29
Start date
2026-10-01
Completion date
2028-12-01
Last updated
2026-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity & Overweight

Keywords

Cardiovascular Risk, Cardiovascular Risk Factors, Endoscopic Sleeve Gastroplasty, Obesity

Brief summary

The primary outcome of this study is to evaluate changes in cardiovascular risk after endoscopic sleeve gastroplasty (ESG) in patients at high cardiovascular risk, using the SCORE2 ( Systematic COronary Risk Evaluation 2) and SCORE2-OP ( Systematic COronary Risk Evaluation 2 Older Persons) risk scores, which estimate the risk of having a cardiovascular event.

Detailed description

This study aims to evaluate whether endoscopic sleeve gastroplasty (ESG), a minimally invasive procedure that reduces the size of the stomach, may improve cardiovascular health in patients with a high risk of cardiovascular disease. Cardiovascular risk refers to the likelihood of developing serious conditions such as heart attack or stroke. In this study, cardiovascular risk will be assessed using two validated risk scores: SCORE2 (Systematic COronary Risk Evaluation 2), used mainly in adults aged 40-69 years, and SCORE2-OP (Systematic COronary Risk Evaluation 2 - Older Persons), used in people aged 70 years and older. Risk modifiers include coronary calcium score (CAC), coronary angiography and the socioeconomic status, as well as the presence of specific comorbidities. Following recent scientific evidence, circulating biomarkers as well as imaging biomarkers like epicardial fat (EAT) characterization, the quantification of oxidative stress and the composition and role of gut microbiota are proposed to stratify and personalize the calculation of Cardiovascular risk (CV) and therefore improve CV prognosis

Interventions

OTHERechocardiography

Echocardiography will be performed in each patient The following parameters will be assessed: systolic function, diastolic function, presence/absence of ventricular hypertrophy, left atrial volume indexed (LAVi), left atrial strain (LAS), valvular morphology and function, estimated intracardiac pressures

Coronary CT angiography has a duration of 10-15 minutes per patient and requires the use of contrast

BIOLOGICALblood analysis

Blood count, liver and kidney function, coagulation assessment, C-reactive protein, glycaemic and lipidic profile

Sponsors

Maria Cecilia Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* informed consent * obesity or overweight * atherosclerotic cardiovascular disease * type 1 or type 2 diabetes mellitus * hypercholesterolemia or severe dyslipidemia * evidence of subclinical atherosclerosis

Exclusion criteria

* chronic inflammatory diseases * active viral or bacterial infections * severe anaemia or severe coagulopathy * severe chronic kidney failure * active malignancy * anticoagulant therapy * chronic treatment with immunosuppressants/immunomodulators * pregnancy

Design outcomes

Primary

MeasureTime frame
Changes in Systematic Coronary Risk Evaluation 2 ( SCORE 2) and Systematic Coronary Risk Evaluation 2 Older Persons (SCORE 2 OP) using algorithms after endoscopic sleeve gastroplasty.From enrollment to the end of follow up at 12 months

Countries

Italy

Contacts

CONTACTElisa Giacomini, PhD
egiacomini@gvmnet.it+39 0545.217688

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Oct 11, 2026